Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis for AMD-related Pigment Epithelial Detachment
NCT00841581Phase 2Completed
- Start
- Dec 2008
- Primary completion
- Sep 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD) and retinal pigment epithelial detachment (PED). Primary endpoint: Best Corrected Visual Acuity at 6 months. Started Dec 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)retinal pigment epithelial detachment (PED)
Beyond the preview
Go deeper on NCT00841581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841581.